These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

544 related items for PubMed ID: 25807831

  • 1. Clinical application of HE4 and CA125 in ovarian cancer type I and type II detection and differential diagnosis.
    Gąsiorowska E, Michalak M, Warchoł W, Lemańska A, Jasiński P, Spaczyński M, Nowak-Markwitz E.
    Ginekol Pol; 2015 Feb; 86(2):88-93. PubMed ID: 25807831
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
    Ren X, Zhang H, Cong H, Wang X, Ni H, Shen X, Ju S.
    Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
    [Abstract] [Full Text] [Related]

  • 4. HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study.
    Romagnolo C, Leon AE, Fabricio ASC, Taborelli M, Polesel J, Del Pup L, Steffan A, Cervo S, Ravaggi A, Zanotti L, Bandiera E, Odicino FE, Scattolo N, Squarcina E, Papadakis C, Maggino T, Gion M.
    Gynecol Oncol; 2016 May; 141(2):303-311. PubMed ID: 26801941
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women.
    Fujiwara H, Suzuki M, Takeshima N, Takizawa K, Kimura E, Nakanishi T, Yamada K, Takano H, Sasaki H, Koyama K, Ochiai K.
    Tumour Biol; 2015 Feb; 36(2):1045-53. PubMed ID: 25326813
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response.
    Hamed EO, Ahmed H, Sedeek OB, Mohammed AM, Abd-Alla AA, Abdel Ghaffar HM.
    Diagn Pathol; 2013 Jan 23; 8():11. PubMed ID: 23343214
    [Abstract] [Full Text] [Related]

  • 8. Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin.
    Stiekema A, Boldingh QJ, Korse CM, van der Noort V, Boot H, van Driel WJ, Kenter GG, Lok CA.
    Gynecol Oncol; 2015 Mar 23; 136(3):562-6. PubMed ID: 25560808
    [Abstract] [Full Text] [Related]

  • 9. Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management.
    Bandiera E, Romani C, Specchia C, Zanotti L, Galli C, Ruggeri G, Tognon G, Bignotti E, Tassi RA, Odicino F, Caimi L, Sartori E, Santin AD, Pecorelli S, Ravaggi A.
    Cancer Epidemiol Biomarkers Prev; 2011 Dec 23; 20(12):2496-506. PubMed ID: 22028406
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
    Karlsen MA, Sandhu N, Høgdall C, Christensen IJ, Nedergaard L, Lundvall L, Engelholm SA, Pedersen AT, Hartwell D, Lydolph M, Laursen IA, Høgdall EV.
    Gynecol Oncol; 2012 Nov 23; 127(2):379-83. PubMed ID: 22835718
    [Abstract] [Full Text] [Related]

  • 14. Development of a multi-marker model combining HE4, CA125, progesterone, and estradiol for distinguishing benign from malignant pelvic masses in postmenopausal women.
    Zhang P, Wang C, Cheng L, Zhang P, Guo L, Liu W, Zhang Z, Huang Y, Ou Q, Wen X, Tian Y.
    Tumour Biol; 2016 Feb 23; 37(2):2183-91. PubMed ID: 26349751
    [Abstract] [Full Text] [Related]

  • 15. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
    Leandersson P, Åkesson A, Hedenfalk I, Malander S, Borgfeldt C.
    PLoS One; 2020 Feb 23; 15(10):e0240418. PubMed ID: 33075095
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparison of HE4, CA125, and Risk of Ovarian Malignancy Algorithm in the Prediction of Ovarian Cancer in Korean Women.
    Cho HY, Park SH, Park YH, Kim HB, Kang JB, Hong SH, Kyung MS.
    J Korean Med Sci; 2015 Dec 23; 30(12):1777-83. PubMed ID: 26713052
    [Abstract] [Full Text] [Related]

  • 18. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?
    Montagnana M, Danese E, Ruzzenente O, Bresciani V, Nuzzo T, Gelati M, Salvagno GL, Franchi M, Lippi G, Guidi GC.
    Clin Chem Lab Med; 2011 Mar 23; 49(3):521-5. PubMed ID: 21288178
    [Abstract] [Full Text] [Related]

  • 19. CPH-I and HE4 Are More Favorable Than CA125 in Differentiating Borderline Ovarian Tumors from Epithelial Ovarian Cancer at Early Stages.
    Wang Z, Tao X, Ying C.
    Dis Markers; 2019 Mar 23; 2019():6241743. PubMed ID: 31737130
    [Abstract] [Full Text] [Related]

  • 20. Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis.
    Bandiera E, Zanotti L, Fabricio AS, Bucca E, Squarcina E, Romani C, Tassi R, Bignotti E, Todeschini P, Tognon G, Romagnolo C, Gion M, Sartori E, Maggino T, Pecorelli S, Ravaggi A.
    Clin Chem Lab Med; 2013 Sep 23; 51(9):1815-24. PubMed ID: 24013103
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.